Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…
Genentech Reintroduces Susvimo Ocular Implant for Wet AMD
Genentech announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant, aimed at treating wet age-related macular degeneration (AMD). This decision follows the FDA’s approval of a post-approval supplement to the Biologics License Application, which…
Outlook Therapeutics Receives UK Approval of Lytenava for AMD
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava is the first and only authorized…
Glaukos Activates CMS J-Code for iDose TR
Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for its iDose TR product. This development marks a significant milestone in enhancing patient access and streamlining coverage and payment processes for the innovative treatment, according…
FDA Greenlights Formycon and Klinge’s Biosimilar to Eylea
Formycon AG and its licensing partner Klinge Biopharma GmbH announced the U.S. Food and Drug Administration’s (FDA) approval of FYB203/AHZANTIVE®, a biosimilar to Eylea®. FYB203/AHZANTIVE® has been approved by the FDA for the treatment of patients with Age-Related Neovascular (wet)…
Beacon Therapeutics Propels Gene Therapy with $170M Funding
Beacon Therapeutics has successfully raised $170 million in Series B funding, marking a significant step forward in advancing its portfolio of ophthalmic gene therapies. The funds are earmarked to support the ongoing clinical development of Beacon’s lead candidate, AGTC-501, designed…
Study Suggests Novel Treatment Approach for Wet AMD
A recent study conducted on mice has provided promising insights into a potential alternative treatment for the “wet” version of age-related macular degeneration (AMD). Researchers identified an enzyme, telomerase, which plays a critical role in the abnormal blood vessel growth…
Alcon Finalizes Acquisition of BELKIN Vision
Alcon has finalized its acquisition of BELKIN Vision, marking a significant expansion of its glaucoma treatment offerings. The acquisition, valued at $81M upfront, with potential additional payments up to $385M contingent on sales milestones, includes BELKIN Vision’s innovative Direct Selective…
Roche’s Vabysmo Receives CHMP Recommendation for RVO
Roche announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of marketing authorization for Vabysmo (faricimab). This recommendation includes the treatment of visual impairment…
What Is Symblepharon? | OBN
What Is Symblepharon? Symblepharon is a medical condition characterized by the adhesion of the conjunctiva, the clear membrane that covers the white part of the eye and the inside of the eyelids, to the cornea, the clear front part of…